唑来膦酸注射液治疗糖尿病骨质疏松患者的疗效研究

Clinical Rearch of Zoledronic Acid Treating 55 Diabetic Patients with Osteoporosis

目的探讨唑来膦酸注射液(ZOL)治疗2型糖尿病(T2DM)骨质疏松患者的临床疗效。方法选择在我院内分泌科住院治疗的55例2型糖尿病骨质疏松患者,给予唑来膦酸注射液治疗12个月后,对比治疗前后腰椎L1-4、股骨颈、股骨大转子、华氏三角区的骨密度(BMD)及治疗前后血清中血钙、血磷、骨钙素(BGP)、骨特异性碱性磷酸酶(BALP),测定治疗前后骨痛症状评分。结果 ZOL联合钙尔奇D治疗12个月后,腰椎L1-4、股骨颈、股骨大转子、华氏三角区的BMD均较前明显升高,差异有统计学意义(P<0.05);BGP较前明显升高,差异有统计学意义(P<0.05);B-ALP较治疗前明显降低,差异有统计学意义(P<0.05);血钙、血磷保持平稳,差异无统计学意义(P>0.05);骨痛症状评分明显改善,差异有统计学意义(P<0.05)。结论唑来膦酸注射液(ZOL)治疗2型糖尿病(T2DM)骨质疏松患者疗效确切,值得推广。

Objective To exploring the clinical effect of zoledronic acid（ ZOL） treating type 2 diabetic patients with oste-oporosis. Methods Radomly choosing 55 type 2 diabetic patients with osteoporosis in endocrinology department in mianyang cen-tral hospital who were treated by zoledronic acid. To compare the changes of BMD（ lumbar spine,femoral neck,femoral greater tro-chanter,faherenheit triangle）、blood Ca、blood P、BGP、B-ALP,Checking the bone syndrome. Results BMD of lumbar spine,fem-oral neck,femoral greater trochanter,faherenheit triangle increased,the difference was statistically significant（P〈0. 05）,the level of BGP increased,the difference was statistically significant（P〈0. 05）,the level of BGP discreased,the difference was statistically significant（P〈0. 05）,the levels of blood Ca and blood P had no change,the difference wasn’t statistically significant（P〉0. 05）, The bone syndrome changed,the difference was statistically significant（P〈0. 05）. Conclusion Zoledronic acid treating type 2 diabetic patients with osteoporosis has good effect which is worth promoting.